616 related articles for article (PubMed ID: 10457868)
41. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance.
Endrikat J; Müller U; Düsterberg B
Contraception; 1997 Mar; 55(3):131-7. PubMed ID: 9115000
[TBL] [Abstract][Full Text] [Related]
42. Effect of four combined oral contraceptives on blood pressure in the pill-free interval.
Nichols M; Robinson G; Bounds W; Newman B; Guillebaud J
Contraception; 1993 Apr; 47(4):367-76. PubMed ID: 8508666
[TBL] [Abstract][Full Text] [Related]
43. Effect of a combination of ethinylestradiol and desogestrel in adolescents with oligomenorrhea and ovarian hyperandrogenism.
Nappi C; Farace MJ; Leone F; Minutolo M; Tommaselli AP; Montemagno U
Eur J Obstet Gynecol Reprod Biol; 1987 Jul; 25(3):209-19. PubMed ID: 2956138
[TBL] [Abstract][Full Text] [Related]
44. Low estrogen oral contraceptives and the hypothalamo-pituitary axis.
De Leo V; Lanzetta D; Vanni AL; D'Antona D; Severi FM
Contraception; 1991 Aug; 44(2):155-61. PubMed ID: 1832628
[TBL] [Abstract][Full Text] [Related]
45. Changes in serum apo-lipoprotein AI and sex-hormone-binding globulin levels after treatment with two different progestins administered alone and in combination with ethinyl estradiol.
Crona N; Silfverstolpe G; Samsioe G
Contraception; 1984 Mar; 29(3):261-70. PubMed ID: 6234148
[TBL] [Abstract][Full Text] [Related]
46. Further studies on pituitary and ovarian function in women receiving hormonal contraception.
Cohen BL; Katz M
Contraception; 1981 Aug; 24(2):159-72. PubMed ID: 6794980
[TBL] [Abstract][Full Text] [Related]
47. Dimeric inhibin serum values as markers of ovarian activity in pill-free intervals.
Renier MA; Vereecken A; Van Herck E; Straetmans D; Ramaekers P; Vanderheyden J; Degezelle H; Buytaert P
Contraception; 1998 Jan; 57(1):45-8. PubMed ID: 9554250
[TBL] [Abstract][Full Text] [Related]
48. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins.
Wiegratz I; Jung-Hoffmann C; Kuhl H
Contraception; 1995 Jun; 51(6):341-6. PubMed ID: 7554973
[TBL] [Abstract][Full Text] [Related]
49. Group comparison of serum ethinyl estradiol, SHBG and CBG levels in 83 women using two low-dose combination oral contraceptives for three months.
Dibbelt L; Knuppen R; Jütting G; Heimann S; Klipping CO; Parikka-Olexik H
Contraception; 1991 Jan; 43(1):1-21. PubMed ID: 1825969
[TBL] [Abstract][Full Text] [Related]
50. Factors affecting pituitary gonadotropin function in users of oral contraceptive steroids.
Scott JA; Brenner PF; Kletzky OA; Mishell DR
Am J Obstet Gynecol; 1978 Apr; 130(7):817-21. PubMed ID: 345817
[TBL] [Abstract][Full Text] [Related]
51. Modulation of ovarian function by an oral contraceptive containing 30 micrograms ethinyl estradiol in combination with 2.00 mg dienogest.
Spona J; Feichtinger W; Kindermann C; Moore C; Mellinger U; Walter F; Gräser T
Contraception; 1997 Sep; 56(3):185-91. PubMed ID: 9347211
[TBL] [Abstract][Full Text] [Related]
52. A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 micrograms and 30 micrograms ethinylestradiol.
Winkler UH; Schindler AE; Endrikat J; Düsterberg B
Contraception; 1996 Feb; 53(2):75-84. PubMed ID: 8838483
[TBL] [Abstract][Full Text] [Related]
53. The response of the pituitary-ovarian axis to pulsatile administration of gonadotropin-releasing hormone in long-term oral contraceptive users.
Hemrika DJ; Slaats EH; Schoemaker J
Am J Obstet Gynecol; 1994 Feb; 170(2):462-8. PubMed ID: 8116698
[TBL] [Abstract][Full Text] [Related]
54. The effects of levonorgestrel, desogestrel and gestodene on the pulsatile release of luteinizing hormone in oral contraceptive users.
Hemrika DJ; Slaats EH; Kennedy JC; de Vries Robles-Korsen TJ; Schoemaker J
Gynecol Endocrinol; 1993 Sep; 7(3):191-200. PubMed ID: 8291457
[TBL] [Abstract][Full Text] [Related]
55. Hemostatic and metabolic effects of lowering the ethinyl-estradiol dose from 30 mcg to 20 mcg in oral contraceptives containing desogestrel.
Basdevant A; Conard J; Pelissier C; Guyene TT; Lapousterle C; Mayer M; Guy-Grand B; Degrelle H
Contraception; 1993 Sep; 48(3):193-204. PubMed ID: 8222650
[TBL] [Abstract][Full Text] [Related]
56. Comparative study on the acceptability of two modern monophasic oral contraceptive preparations: 30 microgram ethinyl estradiol combined with 150 microgram desogestrel or 75 microgram gestodene.
Zichella L; Sbrignadello C; Tomassini A; Di Lieto A; Montoneri C; Zarbo G; Mancone M; Pietrobattista P; Bertoli G; Perrone G
Adv Contracept; 1999; 15(3):191-200. PubMed ID: 11019950
[TBL] [Abstract][Full Text] [Related]
57. Serum gonadotropin and ovarian steroid levels in women during administration of a norethindrone-ethinylestradiol triphasic oral contraceptive.
Ling WY; Johnston DW; Lea RH; Bent AE; Scott JZ; Toews MR
Contraception; 1985 Oct; 32(4):367-75. PubMed ID: 3935373
[TBL] [Abstract][Full Text] [Related]
58. Comparative metabolic effects of three types of combined oral contraceptive pills in Chinese women.
Prasad RN; Liew D; Ratnam SS
Contraception; 1989 Jan; 39(1):21-35. PubMed ID: 2521321
[TBL] [Abstract][Full Text] [Related]
59. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
60. The effect of contraceptive steroids on hypothalamic-pituitary function.
Mishell DR; Kletzky OA; Brenner PF; Roy S; Nicoloff J
Am J Obstet Gynecol; 1977 May; 128(1):60-74. PubMed ID: 403765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
